Suo-Qin Tang

669 citations
41 papers · 570 indexed · h-index 12
Topics
Neuroblastoma Research and Treatments (14 papers)RNA Interference and Gene Delivery (9 papers)Cancer therapeutics and mechanisms (5 papers)

In The Last Decade

Suo-Qin Tang

39 papers receiving 558 citations

Peers

Suo-Qin Tang
Comparison fields: 5 of 84
  • Molecular Biology 295
  • Biomaterials 241
  • Biomedical Engineering 208
  • Oncology 91
  • Immunology 60
Replace Libor Kostka with:
Libor Kostka Czechia
Noah Gorelick United States
Laurel T. Bate-Eya Netherlands
Yue Geng United States
Damiano Librizzi Germany
Xingsu Yu China
Henrike Caysa Germany
Sanja Dimitrijevic Serbia
Ela Markovsky Israel
Siva Kumar Natarajan United States
Suo-Qin Tang relative to Libor Kostka Czechia Libor Kostka's profile →
Citations per field
00.5×1.5×
Libor Kostka · 1×
Citations per year

Countries citing papers authored by Suo-Qin Tang

Since Specialization
Citations

This map shows the geographic impact of Suo-Qin Tang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suo-Qin Tang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suo-Qin Tang more than expected).

Fields of papers citing papers by Suo-Qin Tang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suo-Qin Tang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suo-Qin Tang. The network helps show where Suo-Qin Tang may publish in the future.

Co-authorship network of co-authors of Suo-Qin Tang

This figure shows the co-authorship network connecting the top 25 collaborators of Suo-Qin Tang. A scholar is included among the top collaborators of Suo-Qin Tang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suo-Qin Tang. Suo-Qin Tang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 18
3 4
4 11
5 11
6 97
7 12
8 6
9 6
10 8
11 6
12 8
13 140
14 22
15 1
16 19
17 22
18 7
19
[Effect of topotecan on MAGE gene expression of HPB-AM cells].
1
20 1

About Suo-Qin Tang

Suo-Qin Tang is a scholar working on Neurology, Hematology and Cancer Research, having authored 41 papers that have together received 570 indexed citations. Recurring topics across this work include Neuroblastoma Research and Treatments (14 papers), RNA Interference and Gene Delivery (9 papers) and Cancer therapeutics and mechanisms (5 papers). The work is most often cited by research in Biomaterials (241 citations), Biomedical Engineering (208 citations) and Molecular Biology (295 citations). Suo-Qin Tang has collaborated with scholars based in China, United States and Philippines. Frequent co-authors include Tianyou Wang, Feng Chen, Jinchao Zhang, Yixian Huang, Song Li, Yanhua Liu, Jingjing Sun, Yichao Chen, Anil Kumar and Xing‐Jie Liang. Their work appears in journals such as ACS Nano, Journal of Controlled Release and Pharmaceutical Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026